Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis
A territory-wide electronic public health care database in Hong Kong linked with population-based vaccination records was used to conduct a retrospective cohort study. Adjusted analysis showed that the postvaccination myocarditis group had a 92% lower mortality risk (adjusted HR: 0.08; 95% CI: 0.01-0.57). This study found a significantly lower rate of mortality among individuals with myocarditis after mRNA vaccination compared with those with viral infection–related myocarditis. Prognosis of this iatrogenic condition may be less severe than naturally acquired viral infection–related myocarditis.
Full Access: Journal of American College of Cardiology
CDC expands use of updated COVID-19 vaccines for kids as young as 6 months
The Centers for Disease Control and Prevention (CDC) on Friday signed off on the use of bivalent COVID-19 vaccines for children ages 6 months through 5 years. The vaccine authorization comes amid a rise in COVID-19 infections as well as one of the earliest surges of influenza.
Full Access: The Hill
Urgent Care is Correcting Course on Antibiotic Prescribing
The Urgent Care Association and the College of Urgent Care Medicine introduced their Antibiotic Stewardship program due to the real need for comprehensive antibiotic stewardship across the healthcare industry. All urgent care providers need to take ownership of their prescribing practices and understand the role they play in stewardship efforts. Data showed evidence that urgent care prescribers embraced the challenge.
Full Access: JUCM
WHO recommends new name for monkeypox disease
In support of the November 28, 2022 recommendation by the World Health Organization (WHO)and Health and Human Services (HHS), CDC will adopt “mpox” as the term used to refer to monkeypox disease. Moving forward, U.S. federal public health agencies, including CDC, will adopt the mpox name in correspondence with the medical community and the public. This change from the WHO will enhance the U.S. response to mpox by using a less stigmatizing term. CDC encourages all partners to use the term mpox in all documents, public facing communications, and correspondence.
Full Access: WHO